HIV vaccine - HIVACAT/Esteve

Drug Profile

HIV vaccine - HIVACAT/Esteve

Alternative Names: HIVACAT AIDS vaccine programme - Hospital Clinic de Barcelona/IrsiCaixa Foundation/Esteve

Latest Information Update: 19 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator HIVACAT; irsiCaixa Foundation
  • Developer ESTEVE; HIVACAT; irsiCaixa Foundation
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 19 Jan 2016 Phase-I clinical trials in HIV infections (Prevention) in Spain (unspecified route)
  • 19 Jan 2016 Phase-I clinical trials in HIV infections in Spain (unspecified route)
  • 30 Apr 2010 Preclinical trials in HIV infections (prevention) in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top